Scarica l'app Stockscreener
3.61
1.10%
-0.04
Dopo l'orario di chiusura:
3.51
-0.10
-2.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.65
Aprire:
$3.74
Volume 24 ore:
90,489
Relative Volume:
0.99
Capitalizzazione di mercato:
$62.60M
Reddito:
-
Utile/perdita netta:
$-24.05M
Rapporto P/E:
-1.6791
EPS:
-2.15
Flusso di cassa netto:
$-17.78M
1 W Prestazione:
+1.12%
1M Prestazione:
+64.84%
6M Prestazione:
+3.44%
1 anno Prestazione:
-27.80%
Intervallo 1D:
$3.60
$3.75
Intervallo di 1 settimana:
$3.47
$3.97
Portata 52W:
$2.0278
$6.48
Envveno Medical Corporation Stock (NVNO) Company Profile
Nome
Envveno Medical Corporation
Settore
Industria
Telefono
949-261-2900
Indirizzo
70 DOPPLER, IRVINE
Confronta NVNO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
3.61 | 62.60M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
131.99 | 230.70B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.87 | 154.22B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
388.08 | 145.74B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
85.81 | 107.03B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
74.80 | 44.06B | 5.54B | 4.18B | 623.10M | 7.00 |
Envveno Medical Corporation Borsa (NVNO) Ultime notizie
Geode Capital Management LLC Increases Stake in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
NVNO: Financial Position Supports Key Developments Ahead | NVNO Stock News - GuruFocus
enVVeno Medical (NVNO) Eyes Commercial Transition with VenoValve - GuruFocus
enVVeno Medical Reports First Quarter 2025 Financial Results and - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - Eagle-Tribune
enVVeno Medical Reports Strong Q1 Financials with $38.9M War Chest for VenoValve FDA Launch - Stock Titan
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - ACCESS Newswire
JPMorgan Chase & Co. Buys New Shares in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium | NVNO Stock News - GuruFocus
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium - Weatherford Democrat
enVVeno Medical Corp appoints CBIZ CPAs as new auditor By Investing.com - Investing.com South Africa
enVVeno Medical Corp appoints CBIZ CPAs as new auditor - Investing.com Australia
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment | NVNO Stock News - GuruFocus
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment - Weatherford Democrat
Live Today: enVVeno Medical Unveils Game-Changing Venous Valve Technology - Stock Titan
National Bank of Canada FI Takes $60,000 Position in enVVeno Medical Corporation (NASDAQ:NVNO) - The AM Reporter
enVVeno Medical Promotes Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer - ACCESS Newswire
Financial Analysis: ClearPoint Neuro (NASDAQ:CLPT) vs. enVVeno Medical (NASDAQ:NVNO) - Defense World
NVNO stock touches 52-week low at $2.45 amid market challenges - Investing.com
We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely - simplywall.st
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium - Weatherford Democrat
Virtu Financial LLC Buys Shares of 28,533 enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
VenoValve trial shows sustained patient benefits at 24 months - MSN
Sanctuary Advisors LLC Makes New Investment in enVVeno Medical Corporation (NASDAQ:NVNO) - Defense World
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 - BioSpace
enVVeno Medical (NVNO) to Release Earnings on Thursday - MarketBeat
enVVeno Medical expects capital to fund company through several milestones - TipRanks
enVVeno Medical Files For Mixed Shelf Of Up To $100 MillionSEC Filing - TradingView
enVVeno Medical reports FY24 EPS ($1.27) vs. ($1.91) last year - TipRanks
NVNOEnvveno Medical Corporation Latest Stock News & Market Updates - StockTitan
EnVVeno Medical Reports Fourth Quarter and Year-End 2024 Financi - News Channel Nebraska
Can enVVeno's $43M Cash Runway Carry VenoValve Through FDA Approval? Clinical Data Shows 78% Success Rate - Stock Titan
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing - ACCESS Newswire
enVVeno Medical (NVNO) Projected to Post Quarterly Earnings on Thursday - Defense World
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
enVVeno Medical (NASDAQ:NVNO) Shares Up 6.4%Here's Why - MarketBeat
enVVeno Medical to Present at the Ladenburg Thalmann 2022 Healthcare Conference - ACCESS Newswire
One-year data from VenoValve US pivotal trial highlighting impact on patients’ QoL presented at AVF 2025 - Venous News
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum - BioSpace
enVVeno Announces One Year Data from VenoValve U.S. Pivotal Trial - MPO-mag
Can These 5 Growth Drivers Make enVVeno Medical the Next Big Thing in Venous Disease Treatment? - StockTitan
Envveno Medical Corporation Azioni (NVNO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):